Phyllantus Amarus for the Protection of Liver Health
Phyllantus Amarus for the Protection of Liver Health: A Randomized, Double Blind, Placebo Controlled Crossover Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Northridge, California, United States, 91325
- Medicus Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female 21-50 years of age, inclusive.
- Subject consumes at least 5 servings of alcohol per week on a regular basis.
- Minimum POMS score of 15.
- Access to a computer and internet
- Subject is willing to maintain his or her habitual food and beverage intake (other than substitution of study food for similar products) and physical activity patterns throughout the study period.
- Body mass index (BMI) between 20 and 30 kg/m2.
- Subject is willing and able to comply with the alcohol consumption requirements.
- Subjects willing to stay in the clinic for two overnight stays
- Judged by the Investigator to be in general good health on the basis of medical history.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.
Exclusion Criteria:
- Any Liver condition including Hepatitis, Fatty Liver, Liver Disease.
- Liver Function greater than three times the upper level limit of normal
- History or record of aggressive or violent behavior
- Any significant GI condition that would potentially interfere with the evaluation of the study product [e.g., Ulcerative Colitis or Crohn's Disease, inflammatory bowel disease, irritable bowel syndrome, Clinically significant Gastritis, history of upper GI bleed (bleeding ulcer), chronic constipation (defined as <3 bowel movements per week), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, clinically important lactose intolerance].
- Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, or biliary disorder.
- Known allergy or sensitivity to any ingredients in the study products.
- Extreme dietary habits (e.g., vegan, Atkins Diet, etc.).
- Recent (within two weeks of visit 1, week -1) episode of acute gastrointestinal illness such as nausea, vomiting, or diarrhea.
- Uncontrolled hypertension (systolic blood pressure _160 mm Hg or diastolic blood pressure _100 mm Hg at visit 1, week -1).
- History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- Any major trauma or surgical event within three months of visit 1, week -1.
- Recent use of antibiotics (within 6 weeks).
- Females who are pregnant, lactating, planning to be pregnant during the study period.
- Recent history of (within 12 months) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink =12 ounces beer, 5 ounces wine, or 1 ½ ounces distilled spirits).
- Participation in a clinical study with exposure to any non-registered drug product within 30 days prior.
- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk
- Current active respiratory illness at the time of screening
- Any immune system disorders
- Subjects with a history of perforation of the stomach or intestines
- Subjects who have had gastric bypass surgery
- Untreated Hypothyroidism
- Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders
- Spinal cord injuries
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Active Product then Placebo
|
|
|
EXPERIMENTAL: Placebo then Active Product
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Compare the effect of Phyllantus versus placebo on HS CRP levels in blood
Time Frame: 26 days
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on the inflammatory cytokines in blood
Time Frame: 26 days
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on liver function levels in blood
Time Frame: 26 days
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on glutatoine peroxidase (GSH-Px) in blood
Time Frame: 26 days
|
26 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare the effect of Phyllantus versus placebo on hangover severity score
Time Frame: 26 days
|
26 days
|
|
|
Compare the effect of Phyllantus versus placebo on profile of mood states (POMS)
Time Frame: 26 days
|
26 days
|
|
|
Compare the effect of Phyllantus versus placebo on cognitive performance tests
Time Frame: 26 days
|
Using the CNS Vital Signs System
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on sleep quality
Time Frame: 26 days
|
Based on the number of hours slept
|
26 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Compare the effect of Phyllantus versus placebo on adverse events
Time Frame: 36 days
|
36 days
|
|
Compare the effect of Phyllantus versus placebo on a comprehensive metabolic panel (CMP) analysis
Time Frame: 26 days
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on complete blood count
Time Frame: 26 days
|
26 days
|
|
Compare the effect of Phyllantus versus placebo on Urinalaysis
Time Frame: 26 days
|
26 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Tengku Shahrir Tengku Adnan, Biotropics Malaysia Berhad
- Principal Investigator: Sanjay Udani, MD, Medicus Research, LLC
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BIOT1200
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.